文献速递妇科

卵巢癌临床试验参与中的差异:一项真实世界分析

Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
PubMed 文献 · Gynecol Oncol · 2023-06-08

本研究基于美国约800个学术与社区医疗点的真实世界电子健康记录数据库,回顾性纳入2011至2021年诊断的上皮性卵巢癌患者7540例,采用多变量泊松回归分析临床试验参与的相关因素。结果显示仅5.0%(95% CI 4.5-5.5)的患者曾参与临床试验药物试验,西班牙裔或拉丁裔、种族未知或其他、医疗补助保险及医疗保险参保者参与率均显著低于对应参照组。

要点

  • 卵巢癌患者中仅5.0%(95% CI 4.5-5.5)曾参与临床试验药物试验。
  • 西班牙裔或拉丁裔患者参与临床试验的可能性较非西班牙裔患者低71%(RR 0.29,95% CI 0.13-0.61)。
  • 医疗补助保险参保者较私人保险者参与可能性低51%(RR 0.49,95% CI 0.28-0.87)。

核心结论

  • 在这项全国性队列研究中,仅5%的卵巢癌患者参与了临床试验药物试验。
  • 需要采取干预措施以减少临床试验参与中的种族、族裔和保险差异。

研究设计与样本

  • 回顾性队列研究,使用源自真实世界电子健康记录的数据库,代表美国约800个学术和社区医疗点。
  • 纳入2011年至2021年诊断的上皮性卵巢癌患者7540例。
  • 采用多变量泊松回归模型分析曾参与卵巢癌临床试验药物试验与患者、社会人口学、卫生系统和癌症因素之间的关联。

主要发现

  • 7540例卵巢癌患者中,5.0%(95% CI 4.5-5.5)曾参与临床试验药物试验。
  • 西班牙裔或拉丁裔患者参与临床试验的可能性较非西班牙裔患者低71%(RR 0.29,95% CI 0.13-0.61)。
  • 种族未知或非黑人或白人的患者参与临床试验的可能性较黑人或白人患者低40%(RR 0.68,95% CI 0.52-0.89)。
  • 医疗补助保险参保者参与临床试验的可能性较私人保险参保者低51%(RR 0.49,95% CI 0.28-0.87)。
  • 医疗保险参保者参与临床试验的可能性较私人保险参保者低32%(RR 0.48-0.97,原文未写明该RR的95% CI下限)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Significant disparities exist in clinical trial participation in non-gynecologic cancers, but little is known about disparities in ovarian cancer trial participation. Our objective was to examine patient, sociodemographic (race/ethnicity, insurance), cancer, and health system factors associated with clinical trial participation in ovarian cancer. METHODS: We conducted a retrospective cohort study of patients with epithelial ovarian cancer diagnosed from 2011 to 2021, using a real-world electronic health record derived database, representing around 800 sites of care in US academic and community practices. We used multivariable Poisson regression modeling to analyze the association of ever participating in an ovarian cancer clinical drug trial with patient, sociodemographic, health system, and cancer factors. RESULTS: Of the 7540 patients with ovarian cancer, 5.0% (95% CI 4.5-5.5) ever participated in a clinical drug trial. Patients of Hispanic or Latino ethnicity were 71% less likely to participate in clinical trials (RR 0.29, 95% CI 0.13-0.61) than non-Hispanic patients, and patients whose race was unknown or other than Black or White were 40% less likely to participate in clinical trials (RR 0.68, 95% CI 0.52-0.89). Patients who had Medicaid insurance were 51% less likely (RR 0.49, 95% CI 0.28-0.87) and those with Medicare were 32% (RR 0.48-0.97) less likely to participate in clinical trials than privately-insured patients. CONCLUSION: In this national cohort study, only 5% of patients with ovarian cancer participated in clinical drug trials. Interventions are needed to decrease race, ethnicity, and insurance disparities in clinical trial participation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Smith AJB, Alvarez R, Heintz J, et al. Disparities in clinical trial participation in ovarian cancer: A real-world analysis. Gynecol Oncol. 2023. PMID: 37300995. doi:10.1016/j.ygyno.2023.05.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。